Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

Healthcare is supposed to be the place you hide. It is the fourth-largest slice of U.S. GDP at 8.9% in the fourth quarter of 2025, growing at 1.5% while construction and transportation flatlined. Demand is non-negotiable, cash flows are sticky, and the sector tends to hold up when consumers pull back. That last part matters now: the University of Michigan Consumer Sentiment Index sits at 53.3 in March 2026, well into pessimistic territory.

So why has the Health Care Select Sector SPDR Fund (NYSEARCA:XLV | XLV Price Prediction) lagged so badly? That is the question every portfolio holding it has to answer.

The role XLV is built to play

XLV is the State Street SPDR sector fund that carves the healthcare names out of the S&P 500 and packages them as a single ticker. Holdings are concentrated in large-cap pharmaceuticals, managed care, medical devices, and biotech. The expense ratio has historically run around 0.09%, which keeps it a cheap way to express a sector view.

The intended job is straightforward: lower beta than the broad market, defensive cash flows from drug pipelines and insurance premiums, and a quality tilt that should cushion drawdowns. The return engine is plain-vanilla equity ownership of underlying business cash flows. There are no options overlays, no leverage, no derivatives. You get what the companies earn, plus or minus multiple expansion.

The math is not flattering

Over the past year, XLV returned about 6%. The S&P 500, via SPY, returned roughly 30% over the same window. Stretch the lens to five years and the gap widens: XLV at 27% versus SPY at 71%. Ten-year totals come in at 143% for XLV and 247% for SPY.

Year-to-date in 2026 the divergence continues, with XLV down about 7% while SPY is up about 5%. The defensive promise has shown up in volatility behavior while absolute returns have lagged. With the VIX near 19 and pulling back from a March peak around 31, the environment that historically rewards low-beta sectors has not lifted XLV.

Reddit sentiment reflects the disconnect. Monthly chatter on the ticker shows a sentiment score of 63.5 with low activity, mostly surfacing in r/options threads where traders use XLV for premium-selling rather than long-term conviction holds. It is being treated as a tactical tool.

What you are actually buying

Three tradeoffs deserve attention before adding XLV to a portfolio:

1. Concentration in a politicized sector. Drug pricing, Medicare negotiation, and insurer margin caps are recurring policy risks. A handful of mega-caps in pharma and managed care drive most of the index, so a single regulatory headline can move the whole fund.
2. Period-specific underperformance. Healthcare has lagged in growth-led tape because the index lacks meaningful AI exposure. With CPI running at 330.3 and inflation still above the Fed’s target, multiple compression has hit defensive sectors harder than mega-cap tech.
3. Demand softness during consumer stress. Pessimistic sentiment leads spending by one to three months, and elective procedures, dental visits, and discretionary pharma get cut first. The defensive label still leaves the sector exposed.

XLV makes sense as a 5% to 10% sector sleeve for investors who want lower beta, dividend support, and exposure to demographic tailwinds, but anyone treating it as a substitute for broad-market growth has been paying for that misunderstanding since 2021.